Hsbc Holdings PLC Sells 107,077 Shares of Moderna, Inc. $MRNA

Hsbc Holdings PLC trimmed its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 14.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 638,370 shares of the company’s stock after selling 107,077 shares during the quarter. Hsbc Holdings PLC’s holdings in Moderna were worth $18,911,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRNA. Caitong International Asset Management Co. Ltd boosted its position in Moderna by 21.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 387 shares in the last quarter. Sankala Group LLC acquired a new position in shares of Moderna during the fourth quarter worth $240,000. Virtu Financial LLC bought a new position in shares of Moderna in the 4th quarter valued at $2,425,000. Hamilton Wealth LLC bought a new position in shares of Moderna in the 4th quarter valued at $3,098,000. Finally, Corient Private Wealth LLC boosted its holdings in shares of Moderna by 143.3% during the 4th quarter. Corient Private Wealth LLC now owns 68,256 shares of the company’s stock valued at $2,013,000 after acquiring an additional 40,202 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $60.42 on Thursday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $67.74. The company has a market capitalization of $23.97 billion, a price-to-earnings ratio of -7.41 and a beta of 1.05. The stock has a 50 day moving average of $51.12 and a 200 day moving average of $46.13. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same quarter in the previous year, the firm earned ($2.52) earnings per share. The business’s quarterly revenue was up 260.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Moderna, Inc. will post -6.51 earnings per share for the current year.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at $183,800.16. The trade was a 70.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Stephen Hoge sold 53,336 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 125,088 shares of company stock worth $6,193,713. 10.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research reports. The Goldman Sachs Group raised their price objective on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Royal Bank Of Canada upped their price target on shares of Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research report on Thursday, June 18th. Finally, Bank of America upped their target price on Moderna from $32.00 to $34.00 and gave the company an “underperform” rating in a research report on Monday, June 8th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $36.60.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.